Undifferentiated Endometrial Carcinoma, an Immunohistochemical Study Including PD-L1 Testing of a Series of Cases From a Single Cancer Center
| Autor: | Ghadeer Abdeen, Imad Jaradat, Lian Otay, Shaymaa Al-Loh, Mousa El Khaldi, Osama Badran, Abdulmajeed Dayyat, Isam Lataifeh, Areej Abu Sheikha, Maysa Al-Hussaini |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
0301 basic medicine medicine.medical_specialty Pathology Serous carcinoma medicine.medical_treatment Gastroenterology B7-H1 Antigen Pathology and Forensic Medicine 03 medical and health sciences Cytokeratin 0302 clinical medicine Internal medicine Carcinosarcoma Biomarkers Tumor medicine Carcinoma Humans Survival rate Aged Aged 80 and over Hysterectomy business.industry Obstetrics and Gynecology Cancer Middle Aged medicine.disease Immunohistochemistry Endometrial Neoplasms Survival Rate 030104 developmental biology 030220 oncology & carcinogenesis Female business |
| Zdroj: | International Journal of Gynecological Pathology. 37:564-574 |
| ISSN: | 0277-1691 |
| Popis: | Undifferentiated endometrial carcinoma (UEC) is a rare and poorly recognized entity, associated with a poor outcome. The clinical, pathologic, and immunohistochemical features of 17 cases diagnosed at our center are described. The median age was 60 yr. Postmenopausal bleeding was the most common presenting symptom (76.9%). Most patients presented with advanced stage (64.7%). Total hysterectomy with bilateral salpingo-oophorectomy was the commonly offered surgical treatment (80.0%). Nine (52.9%) patients received adjuvant treatment. The median overall survival was 11 mo. Pure UEC was seen in 8 cases (47.0%), while dedifferentiated carcinoma in 5 cases (29.4%). The epithelial component was part of carcinosarcoma or was mixed with serous carcinoma in 2 cases (11.8%) each. Positivity for one or more of the cytokeratin cocktails, mostly as strong focal staining, was evident in 16 cases (94.1%). PAX-8 was negative in 13 cases (86.7%). BRG-1/SMARCA4 was lost in 3 cases (20.0%). Eleven cases (64.7%) were MLH1/PMS2 deficient. Ten cases (66.7%) were positive for programmed death ligand 1, with positivity in 10%, 20%, and 100% of tumor cells detected in a single case each. Only 2 of 11 (18.2%) referral cases were correctly diagnosed as UEC. UEC is a rare tumor that is frequently misdiagnosed. A panel of immunostains is necessary to make the correct diagnosis. The range of positivity for programmed death ligand 1 testing suggests that immunotherapy might be considered in the adjuvant setting, especially with the poor response of this tumor to traditional therapies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|